BridgeBio Pharma

BridgeBio Pharma

Yahoo Finance • 2 days ago

Panic grips Ionis Pharmaceuticals investors amid bad news spree

A single failed trial can undo years of work in one trading session, and Ionis Pharmaceuticals (IONS) just went through both consecutively. Ionis Pharmaceuticals lost nearly a quarter of its value on July 9 after its heart drug Wainua fai... Full story

Yahoo Finance • 4 days ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on July 7... Full story

Yahoo Finance • 5 days ago

Why AstraZeneca Crashed 8%, Leading Three Rivals, Including Pfizer, To Jump

AstraZeneca stock crashed Thursday after its Ionis-partnered treatment for a rare heart disease failed in Phase 3 testing. Continue Reading... Full story

Yahoo Finance • 5 days ago

Pfizer, Alnylam, BridgeBio gain after late-stage trial setback for Astra/ Ionis

Oselote/iStock via Getty Images Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), Alnylam Pharma (ALNY [https://seekingalpha.com/symbol/ALNY]), and BridgeBio Pharma (BBIO [https://seekingalpha.com/symbol/BBIO]), which market drugs for a... Full story

Yahoo Finance • 16 days ago

BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia

- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically significant improvement versus placebo (LS... Full story

Yahoo Finance • 22 days ago

BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026

PALO ALTO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions... Full story

Yahoo Finance • last month

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Boyd Gaming, Chipotle Mexican Grill, Conagra, Dollar General, MGM Resorts International, Omnicom Group, Yum! Brands, and More

Quick Read: The AI/Data Center chip rally continued to drive the market higher on Tuesday. Now, legacy tech old-school tech giants are joining the rally, as Hewlett Packard Enterprises had its biggest day ever. Despite the giddy, never-en... Full story

Yahoo Finance • last month

Yum! Brands upgraded, Chipotle downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Morgan Stanley upgraded Yum! Brands(YU... Full story

Yahoo Finance • 2 months ago

Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn’t a Slam Dunk

Quick Read BridgeBio Pharma (BBIO) received a Neutral initiation from Citi, signaling caution on BridgeBio despite 22 buy ratings on the stock and Q1 2026 Attruby revenue of $180.6M, up 399% year over year. Citi’s cautious stance reflects... Full story

Yahoo Finance • 2 months ago

StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Guggenheim upgraded StubHub (STUB) to... Full story

Yahoo Finance • 2 months ago

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1 - All pre-specified primary and key secondary effi... Full story

Yahoo Finance • 2 months ago

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure

-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p<0.001), which is associated with reduced ACM, further reinforcing its differentiated profile in ATTR-CM -Acoramidis further dem... Full story

Yahoo Finance • 2 months ago

A Look At BridgeBio Pharma (BBIO) Valuation After Recent Trading Weakness And Pipeline Expectations

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. BridgeBio Pharma stock snapshot after recent trading performance... Full story

Yahoo Finance • 2 months ago

BridgeBio to Participate in May and June Investor Conferences

PALO ALTO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of... Full story

Yahoo Finance • 2 months ago

BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil

- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date, including: - By Month 1, numeric... Full story

Yahoo Finance • 3 months ago

Sector Update: Health Care Stocks Mixed Late Afternoon

Health care stocks were mixed late Thursday afternoon, with the NYSE Health Care Index adding 0.1% a PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

Sector Update: Health Care Stocks Advance in Afternoon Trading

Health care stocks advanced Thursday afternoon, with the NYSE Health Care Index adding 0.3% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 3 months ago

Texas Instruments upgraded, Circle downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Stifel upgraded Texas Instruments (TXN... Full story

Yahoo Finance • 3 months ago

Mizuho Lifts PT on BridgeBio Pharma (BBIO) to $106 From $91 – Here’s Why

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the best high growth healthcare stocks to buy now. Mizuho lifted the price target on BridgeBio Pharma, Inc. (NASDAQ:BBIO) to $106 from $91 on March 18, reiterating an Outperform rating on the... Full story

Yahoo Finance • 4 months ago

Will New Long-Term ATTRibute-CM Data on Acoramidis Shift BridgeBio Pharma's (BBIO) Narrative?

BridgeBio Pharma has announced that long-term efficacy and safety data from the open-label extension of its Phase 3 ATTRibute-CM trial of transthyretin stabilizer acoramidis in ATTR-CM, along with three supporting posters and real-world su... Full story